Australia for Early Phase Clinical Development

May 16, 2018

Novotech and CoSec will be onsite to discuss the advantageous Australian regulatory landscape for early phase clinical development. Fast regulatory timelines and the 43.5% research and development Tax Rebate make Australia an ideal destination for small biotech companies entering clinical trials.

Alex Ireland, MPH
Business Development Associate

Alex Ireland has been working in the biotech industry for the past five years from sales to operations, and has been working for Novotech for the past year. She is passionate about working with small-biotech companies and educating them on the benefits of running clinical trials in the Asia Pacific. Born and raised in the Bay Area, she earned a Master’s Degree from Boston Pharmaceuticals in Epidemiology and International Health.